N=178   Sd SE Min Max Cv CI
OC1 31.79 12.76 .96 4.1 78.9 40.15 29.90-33.67
CL1 551.23 268.11 20.09 18.8 1290.0 48.64 511.57-590.90
OC2 20.96 9.86 .74 3.0 63.6 47.06 19.50-22.42
CL2 200.89 144.31 10.82 10.0 712.6 71.83 179.54-222.24
Assymetry and flattening values ranging from -.04 to .04 were not discussed.
Minimal (min) i maximal (max) values of bone markers of participants compared to the sample of 178 participants indicate that the values are within the expected range. Larger values of coefficient of variation denote that there is heterogeneity compared to the sample of 178 participants in terms of: OC1 (40.15), CL1 (48.64), OC2 (47.06), CL2 (71.83). There is significant statistical difference between starting values and therapeutic ones for both biochemical bone markers (p<0.000). Also, the percentage of osteocalcin change is 34.07%, and the percentage of βCTx change is 63,56% which exceeds values of least significant change (LSC), necessary to conclude that the difference is the effect of receiving bisphosphonate therapy
Table 4: Average values of tested laboratory parameters before the therapy and during it: osteocalcin (OC1 and OC2), βCTx (CL1 and CL2) for 178 clinical participants receiving bisphosphonate therapy.